Not recruiting
Dermatitis atopic
Not recruitingInvestigational
JNJ-95597528 for Adults with Moderate to Severe Atopic Dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:–
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
Find therapies in clinical trials near you – page 3
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
39 trials match your criteria
Not recruiting
Skin wrinkling
Not recruitingInvestigational
Corabotase for Moderate to Severe Glabellar Lines in Adults
Investigational
- Disease:Skin wrinkling
- Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
Not recruiting
Hidradenitis
Not recruitingInvestigational
Study on the Effectiveness and Safety of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:Sonelokimab
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Sonelokimab
Not recruiting
Dermatitis atopic
Not recruitingRegistered drug
Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments
Registered drug
- Disease:Dermatitis atopic
- Substances:AmlitelimabPimecrolimus+1
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Amlitelimab
Not recruiting
Psoriasis
Not recruitingInvestigational
Study on Guselkumab for Patients with Moderate-to-Severe Plaque Psoriasis
Investigational
- Disease:Psoriasis
- Substances:Guselkumab
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Guselkumab
Not recruiting
Hidradenitis
Not recruitingInvestigational
Study of Eltrekibart for Adults with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:Humanised Igg4 Kappa Monoclonal Antibody Against Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Cxcl7 And Cxcl8
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Humanised Igg4 Kappa Monoclonal Antibody Against Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Cxcl7 And Cxcl8
Not recruiting
Psoriasis
Not recruitingRegistered drugNo placebo
Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy
Registered drugNo placebo
- Disease:Psoriasis
- Substances:DeucravacitinibRisankizumab
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Deucravacitinib
Not recruiting
Dermatitis atopic
Not recruitingInvestigationalNo placebo
Study on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis
InvestigationalNo placebo
- Disease:Dermatitis atopic
- Substances:Upadacitinib
Countries:Germany
Germany- Participants:18–64 years
- Substances:Upadacitinib
Not recruiting
Hand dermatitis
Not recruitingInvestigational
Study on the Effectiveness and Safety of Ruxolitinib Cream for Adults with Chronic Hand Eczema
Investigational
- Disease:Hand dermatitis
- Substances:Ruxolitinib
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Ruxolitinib
Not recruiting
Dermatitis atopic
Not recruitingRegistered drug
Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema
Registered drug
- Disease:Dermatitis atopic
- Substances:HydrocortisonePimecrolimus+4
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Hydrocortisone
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
Study on the Effects of LEO 138559 for Adults with Moderate-to-Severe Atopic Dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:Humanised Igg1 Monoclonal Antibody Against Interleukin 22 Receptor Subunit Alpha
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Humanised Igg1 Monoclonal Antibody Against Interleukin 22 Receptor Subunit Alpha
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema
Investigational
- Disease:Dermatitis atopic
- Substances:Upadacitinib
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Upadacitinib